Q1 2025 Biofrontera Inc Earnings Call Transcript
Key Points
- Biofrontera Inc (BFRI) reported a 9% increase in total revenues for the first quarter of 2025, reaching $8.6 million.
- The company successfully reduced its cost of revenue and operating costs compared to the same period in the previous year.
- A new formulation of Ameluz, free from the allergen propylene glycol, has been granted a patent, providing protection until December 2043.
- Biofrontera Inc (BFRI) achieved key milestones in clinical trials, including the final patient enrollment for a Phase 3 trial of Ameluz for actinic keratosis and completion of a one-year follow-up for basal cell carcinoma treatment.
- The company increased its EBITDA and gross profit, supporting its goal of reaching breakeven quickly.
- Biofrontera Inc (BFRI) reported a net loss of $4.2 million for the first quarter of 2025, although this was an improvement from the previous year's loss.
- The company experienced a decrease in cash and cash equivalents, dropping to $1.8 million as of March 31, 2025, from $5.9 million at the end of 2024.
- Research and development expenses increased by $1.2 million compared to the previous year, driven by the assumption of all clinical trial activities for Ameluz in the United States.
- Legal expenses increased by $1.2 million due to patent claims, partially offsetting savings in other areas.
- The sales force experienced some turnover, and the company is working on restructuring its commercial team to improve efficiency.
Good day and welcome to the Biofrontera's First Quarter of 2025 Financial Results and business update conference call. All participants will be in listen-only mode.
(Operator Instructions)
I would now like to turn the conference over to Andrew Barwicki. Please go ahead.
Good morning and welcome to Biofrontera Incorporates First Quarter Fiscal year 2025 Financial results and business update conference call. Please note that certain information discussed during today's call by management is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act.
We caution listeners that Biofrontera's management will be making forward-looking statements and that actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.
All risks and uncertainty are detailed in and are qualified by the cautionary statements contained in Biofrontera's press
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
